Academic Appointments

Honors & Awards

  • Clinical Scientist in Nephrology Fellowship Award, American Kidney Fund (7/2022-7/2024)

Boards, Advisory Committees, Professional Organizations

  • Board-Certified Member, American Board of Internal Medicine, Nephrology (2023 - Present)
  • Board-Certified Member, American Board of Internal Medicine (2021 - Present)

Contact

  • Academic
    jc3@stanford.edu
    University - Scholar Department: School of Medicine Position: Postdoctoral Scholar
    University - Staff Department: Medicine - Med/Nephrology Position: Clinical Scholar

Additional Info

  • Mail Code: 5851

All Publications

  • Immunologic Benefits of 0-antigen Mismatched Transplants: No Added Boost for Racial and Ethnic Minorities. Transplantation direct Caldwell, J. S., Parvathinathan, G., Stedman, M. R., Ahearn, P., Tan, J. C., Cheng, X. S. 2024; 10 (7): e1653

    Abstract

    Systemic barriers to posttransplant care, including access to immunosuppressant medications, contribute to higher rates of kidney transplant failure in racial minorities. Matching donor and recipient HLA alleles reduce allorecognition, easing reliance on immunosuppression. We hypothesize that 0-antigen mismatch transplants may provide stronger protection against graft loss in racial minorities.We compared adult, single-organ, deceased-donor kidney transplants in the United States from 2007 to 2016 by degree of HLA mismatch (0- versus ≥1-antigen mismatch). We examined time-to-allograft failure, with death as a competing event, using multivariable Weibull models, stratified by recipient race (White versus non-White), and evaluated the interaction between mismatch and recipient race. We used Kaplan-Meier imputation to account for competing risk of death.We analyzed 102 114 transplants (median follow-up, 5.6 y; 16 862 graft losses, 18 994 deaths). Zero-antigen mismatch was associated with improved allograft survival (adjusted subdistribution hazard ratio [sHR] 0.80; 95% confidence interval [CI], 0.75-0.85). When stratified by recipient race, the effect of 0-antigen mismatch was more pronounced in White (unadjusted sHR 0.78; 95% CI, 0.72-0.83) versus non-White recipients (sHR 0.88; 95% CI, 0.79-0.99; interaction P = 0.04). The differential effect was attenuated after adjusting for covariates (sHR 0.78; 95% CI, 0.73-0.84 versus sHR 0.87; 95% CI, 0.77-0.98; interaction P = 0.10).Zero-antigen mismatch transplants conferred a 20% risk reduction in allograft loss, which was similar between non-White and White recipients. This may reflect an increased degree of mismatch at other HLA alleles and non-HLA alleles in non-White recipients or because of the extent of systemic barriers to healthcare borne by minority recipients.

    View details for DOI 10.1097/TXD.0000000000001653

    View details for PubMedID 38881747

    View details for PubMedCentralID PMC11177818

  • Maximizing Utility of Deceased Donor Kidney Offers. Clinical journal of the American Society of Nephrology : CJASN Caldwell, J. S., Cheng, X. S. 2023; 18 (12): 1521-1523

    View details for DOI 10.2215/CJN.0000000000000349

    View details for PubMedID 38064304

  • Maximizing Utility of Deceased Donor Kidney Offers. Clinical journal of the American Society of Nephrology : CJASN Caldwell, J. S., Cheng, X. S. 2023

    View details for DOI 10.2215/CJN.0000000000000349

    View details for PubMedID 37930931